|
ID |
Assay Type |
Cell Type |
|
1 |
Mixed Lymphocyte Reaction (MLR) |
Primary human/mouse DC + T cells |
|
2 |
CMV antigen recall |
Primary human T cells |
|
3 |
T cell activation (anti-CD3/CD28) |
Primary human/mouse T cells |
|
4 |
T cell activation (SEB super-antigen) |
Primary human T cells |
|
5 |
T cell and tumor cell co-culture |
Primary human T cells + engineered tumor cells |
|
6 |
OT-I T cell and OVA tumor cell co-culture |
T cells from OT-I mice + OVA-expressing tumor cells |
|
7 |
Treg suppressive assay |
Primary mouse T cells |
|
8 |
Treg differentiation |
Primary human/mouse T cells |
|
9 |
Th1 differentiation |
Primary human/mouse T cells |
|
10 |
Th2 differentiation |
Primary human/mouse T cells |
|
11 |
Th17 differentiation |
Primary human/mouse T cells |
|
12 |
M1/M2 Macrophage differentiation |
Primary human/mouse macrophages |
|
13 |
Macrophage phagocytosis |
Primary human/mouse macrophages |
|
14 |
Mouse T cell and M2 Macrophage co-culture |
Mouse T cells + M2 Macrophages |
|
15 |
NLRP3 activation assay |
Mouse BMDM, human THP-1 cells |
|
16 |
Basophil activation assay |
Human whole blood |
|
17 |
B cell activation and proliferation |
Primary human/mouse B cells or whole blood |
|
18 |
Target specific reporter gene assay (41BB, etc.) |
Engineered cell lines |
|
19 |
Antibody-Dependent Cellular Cytotoxicity (ADCC) |
Primary human NK or NK-92-CD16 + target cells |
|
20 |
NK cell cytotoxicity |
Primary human NK or NK-92-CD16 + target cells |
|
21 |
Complement Dependent Cytotoxicity (CDC) |
Complement + target cells |
|
22 |
ELISpot |
Primary human PBMCs or mouse T cells or splenocytes or TILs Treated with anti-CD3 or peptides or peptide loaded APC or target cells |
